Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06136884
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-11-07
Brief Title:
A First-In-Human Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor AO-252 in Advanced Solid Tumors
Sponsor:
A2A Pharmaceuticals Inc
Organization:
A2A Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Endometrial Cancer |
| Triple Negative Breast Cancer |
| High Grade Serous Ovarian Cancer |
Keywords: